--- config: sankey: showValues: false linkColor: target width: 800 height: 1000 nodeAlignment: right --- sankey-beta RNA-seq/exome, 2011, 15 2011, morin 2011, 15 exome, 2011, 7 2011, pasqualucci 2011a, 7 pasqualucci 2011a, DLBCL Tier 1, 5 pasqualucci 2011a, DLBCL Tier 2, 2 2011, pasqualucci 2011b, 2 pasqualucci 2011b, DLBCL Tier 1, 2 exome, 2012-exome, 4 2012-exome, lohr 2012, 4 lohr 2012, DLBCL Tier 2, 1 lohr 2012, DLBCL Tier 1, 3 WGS, 2013-WGS, 40 2013-WGS, morin 2013, 40 morin 2013, DLBCL Tier 2, 29 morin 2013, DLBCL Tier 1, 11 exome, 2013-exome, 19 2013-exome, zhang 2013, 19 zhang 2013, DLBCL Tier 1, 11 zhang 2013, DLBCL Tier 2, 8 exome, 2016-exome, 2 2016-exome, mareschal 2016, 2 mareschal 2016, DLBCL Tier 1, 2 exome, 2016-exome, 2 2016-exome, morin 2016, 2 morin 2016, DLBCL Tier 1, 2 2017-exome, albuquerque 2017, 3 albuquerque 2017, DLBCL Tier 1, 3 exome, 2017-exome, 63 2017-exome, reddy 2017, 60 reddy 2017, DLBCL Tier 2, 50 reddy 2017, DLBCL Tier 1, 10 exome, 2018-exome, 35 2018-exome, schmitz 2018, 16 schmitz 2018, DLBCL Tier 2, 7 schmitz 2018, DLBCL Tier 1, 9 2018-exome, chapuy 2018, 19 chapuy 2018, DLBCL Tier 2, 16 chapuy 2018, DLBCL Tier 1, 3 WGS, 2018-WGS, 20 2018-WGS, arthur 2018, 20 arthur 2018, DLBCL Tier 2, 12 arthur 2018, DLBCL Tier 1, 8 exome, 2020-exome, 2 2020-exome, pararajalingam 2020, 2 pararajalingam 2020, DLBCL Tier 1, 2 WGS, 2021-WGS, 23 2021-WGS, hubschmann 2021, 23 hubschmann 2021, DLBCL Tier 1, 4 hubschmann 2021, DLBCL Tier 2, 19

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.